Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.

ABSTRACT: Conventional frontline treatment for ovarian cancer consists of successive chemotherapy cycles of paclitaxel and platinum. Despite the initial favorable responses for most patients, chemotherapy resistance frequently leads to recurrent or refractory disease. New treatment strategies that circumvent or prevent mechanisms of resistance are needed to improve ovarian cancer therapy. We established in vitro paclitaxel-resistant ovarian cancer cell line and organoid models. Gene expression differences in resistant and sensitive lines were analyzed by RNA sequencing. We manipulated candidate genes associated with paclitaxel resistance using siRNA or small molecule inhibitors, and then screened the cells for paclitaxel sensitivity using cell viability assays. We used the Bliss independence model t

SUBMITTER: McCorkle JR 

PROVIDER: S-EPMC8336885 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature